1996 Scientific Meeting of the British Thoracic Society

Thorax

Volumn 52, Issue 2, 1997, Pages 109-110

  Catterall, J R ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; HUMAN; INFLUENZA; LUNG CANCER; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REHABILITATION; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; SLEEP APNEA SYNDROME;

EID: 0031038005     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Hopkin JM, Enomoto T, Shimazu S, Shirakawa T. Inverse association between tuberculin responses and atopic disorder. Thorax 1996;51(Suppl 3):A1.
2. Holt PG. Regulation of T-cell response to inhaled antigens. Eur Respir Rev 1996;36,128-35.
3. Seaton A, Soutar A. Antioxidants and bronchial reactivity. Thorax 1996; 51(Suppl 3):A1.
4. Kelly YJ, Brahin BJ, Nair G, Burgess L, Pearson MG. Antioxidant status in children with different respiratory symptoms. Thorax 1996;51(Suppl 3):A15.
5. Spanevello A, Sharara AM, Bianchi A, Myers JD, Bridge P, Pisati P, et al. Reproducibillty of induced sputum cell counts and fluid phase ECP. Thorax 1996;51(Suppl 3):A80.
6. Jatakanon A, Barnes PJ. Induced sputum profiles in asthma of differing seventy. Thorax 1996;51(Suppl 3):A80.
7. Barnes PJ, Kharitonov SA. Exhaled nitric oxide: a new lung function test. Thorax 1996;51:233-7.
8. Chambers DC, Tunnicliffe WS, Fletcher TJ, Ayres JG. Measurement of lower respiratory tract nitric oxide: validity of using values at 75% of exhaled volume. Thorax 1996;51(Suppl 3):A17.
9. Ho LP, Innes JA, Greening AP. Exhaled nitric oxide (NO) is not elevated in patients with cystic fibrosis or bronchiectasis compared to normals. Thorax 1996;51(Suppl 3):A19.
10. O'Donnell DM, Keatings VM, O'Connor C, McLoughlin P, FitzGerald MX. Exhaled nitric oxide is normal in sarcoidosis patients with active alveolitis. Thorax 1996;51(Suppl 3):A18.
11. Smith RP, Rudkin ST, White RJ. Do anxiety and depression affect outcome of rehabilitation in severe chronic obstructive pulmonary disease. Thorax 1996;51(Suppl 3):A25.
12. Garrod R, Bestall JC, Garnham R, Paul EA, Jones PW, Wedzicha JA. Randomised controlled trial of outpatient pulmonary rehabilitation in COPD: preliminary results. Thorax 1996;51(Suppl 3):A24.
13. Singh SJ, Williams J, Morgan MDL. Administration of the Chronic Respiratory Disease Questionnaire: the importance of identifying previous responses. Thorax 1996;51(Suppl 3):A25.
14. Stradling JR, Jenkinson C, Petersen S. Quality of life before and after nasal continuous positive airway pressure (NCPAP) treatment for obstructive sleep apnoea (OSA). Thorax 1996;51(Suppl 3):A4.
15. Gibson GJ, Douglas NJ, Stradling JR. Facilities for investigation and treatment of sleep apnoea in the UK. Thorax 1996;51(Suppl 3):A4.
16. Holmes WF, Macfarlane JT, Macfarlane RM, Lewis S. The influence of antibiotics and other factors on reconsultation for acute lower respiratory tract illness in primary care. Thorax 1996;51(Suppl 3):A13.
17. Macfarlane JT, Holmes WF, Macfarlane RM. Acute lower respiratory tract illness (LRT) in general practice: a study of the view of 787 patients and their influence on antibiotic prescribing. Thorax 1996;51(Suppl 3):A13.
18. Fletcher T, Tunnicliffe W, Hammond K, Roberts K, Ayres JG. The simultaneous administration of influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in patients with chronic respiratory disease. Thorax 1996;51(Suppl 3):A14.
19. Bourke SJ, Reid DW, Bromly CL, Leitch N, Stenton SC, Hendrick DJ. The effect of influenza vaccination on airway responsiveness in patients with stable asthma. Thorax 1966;51(Suppl 3):A2.
20. Pickles H, Rudolf M. Lung cancer: local review of services. Thorax 1996; 51(Suppl 3):A57.
21. Mearns A, Allen MB. Cancer care delivery: are the standards in the Whitehouse report attainable? Thorax 1996;51(Suppl 3):A7.
22. Deegan PC, Stevens S, Heath L, Brunskill J, Kinnear WJM, Johnston IDA. Waiting times in lung cancer: what is achievable by a multidisciplinary team? Thorax 1996;51:(Suppl 3):A7.
23. Warburton CJ, Ryland I, Cooper A, Earis JE. Lung cancer service provision in a large teaching hospital. Thorax 1996;51(Suppl 3):A57.
24. Connolly CK, Johnston CF, Rider PL. Histological confirmation rates and survival in lung cancer in Yorkshire. Thorax 1996;51(Suppl 3):A56.
25. Spiro SG. Clinical trials in lung cancer optimism versus nihilism. Thorax 1997;52(in press).
26. Gabbay E, Nkere U, Wrightson N, Gould FK, Dark JII, Corris PA. Results of pulmonary transplantation in patients with cystic fibrosis colonised by multiply resistant pseudomonads. Thorax 1996;52(Suppl 3):A23.
27. Chadwick SL, Kingston HD, O'Connor BJ, Chent SH, Meeker D, Geddes DM. et al. Safety of aerosol administration of escalating doses of a cationic lipid (lipid 67) formulation to the lungs of normal volunteers. Thorax 1996;(Suppl 3):A6.
28. Alton EWFW, Chadwick SL, Smith SN, Stearn M, Pastorino U, Scallan M, et al. Lower airway potential difference measurements in non-CF and CF subjects. Thorax 1996;51(Suppl 3):A6.
29. Hillery E, Cheng S, Geddes DM, Alton EWFW. Divided doses of DNA: liposome complexes produce suboptimal gene expression for a given DNA dose. Thorax 1996;51(Suppl 3):A5.
30. Kitson C, Huang L, Sorgi F, Geddes DM, Alton HWFW. In vitro and ex vivo approaches to determining the mechanisms of liposome-mediated gene transfer. Tharax 1996;51(Suppl 3):A5.
31. Lukacs KV, Pardo O, Porter C, Browning J, Caplen NJ, Manvell M, et al. In vivo transfer of the β-galactosidase gene into malignant mesothelioma cells induces tumour rejection. Thorax 1996;51(Suppl 3):A6.
32. Koyama H, Caplen NJ, Cheng S, Sorgi F, Huang L, Geddes DM, et al. Human alpha I-antitrypsin gene transfer with cationic liposomes in vitro and in vivo. Thorax 1996;51(Suppl 3):A6.